Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 10,000 Shares of Company Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $104.97, for a total value of $1,049,700.00. Following the completion of the sale, the senior vice president directly owned 14,219 shares in the company, valued at approximately $1,492,568.43. The trade was a 41.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, October 12th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The stock was sold at an average price of $80.60, for a total value of $805,919.40.
• On Monday, September 21st, Arjun Agarwal sold 533 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.75, for a total value of $51,034.75.
• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.71, for a total transaction of $53,597.60.
• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.23, for a total transaction of $872,403.57.

Oruka Therapeutics Price Performance

ORKA stock traded up $0.36 during trading on Friday, hitting $105.35. The stock had a trading volume of 679,678 shares, compared to its average volume of 1,033,539. Oruka Therapeutics, Inc. has a twelve month low of $25.23 and a twelve month high of $115.51. The stock has a market capitalization of $7.14 billion, a P/E ratio of -49.93 and a beta of -0.34. The company’s 50-day moving average price is $89.68 and its two-hundred day moving average price is $72.36.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). As a group, sell-side analysts expect that Oruka Therapeutics, Inc. will post -2.52 EPS for the current fiscal year.

Trending Headlines about Oruka Therapeutics

Here are a few of the latest headlines about ORKA:

• Positive Sentiment: BTIG Research and UBS each assigned Oruka a “Buy” rating, providing a positive analyst view. BTIG Research Buy rating UBS Buy rating
• Negative Sentiment: HC Wainwright cut its estimates for every quarter of 2027 and for full-year 2026 and 2027, while keeping its Buy rating. It now expects losses of $2.69 per share in FY2026 and $3.22 in FY2027, versus prior estimates of $2.54 and $2.82, respectively. The deeper projected losses may dampen sentiment.
• Negative Sentiment: Director Kristine M. Ball sold 18,000 shares—half her position—and SVP Arjun Agarwal sold 10,000 shares, reducing his holdings by 41.29%. Both sales were made under pre-arranged Rule 10b5-1 plans, which may lessen their significance as a signal about near-term prospects. Director Form 4 filing SVP Form 4 filing

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter worth $2,874,000. Sei Investments Co. raised its holdings in shares of Oruka Therapeutics by 136.0% during the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock worth $1,120,000 after acquiring an additional 13,164 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Oruka Therapeutics by 517.1% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,310 shares of the company’s stock valued at $9,927,000 after acquiring an additional 87,408 shares during the last quarter. Braidwell LP acquired a new position in shares of Oruka Therapeutics during the 2nd quarter valued at about $26,473,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Oruka Therapeutics during the 1st quarter valued at about $5,543,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Analysts Set New Price Targets

ORKA has been the subject of a number of research reports. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Wedbush reissued an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. HC Wainwright restated a “buy” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Finally, BTIG Research reaffirmed a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, November 10th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $141.80.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.